6zs8

Publication Abstract from PubMed

Arsenoplatin-1 (AP-1) is an innovative dual-action anticancer agent that contains a platinum(ii) center coordinated to an arsenous acid moiety. We found that AP-1 spontaneously aggregates in aqueous solutions generating oligomeric species of increasing length. Afterward, we succeeded in solving the crystal structure of the adduct formed between the model protein lysozyme and an early AP-1 oligomer that turned out to be a trimer. Remarkably, this crystal structure traps an early stage of AP-1 aggregation offering detailed insight into the molecular process of the oligomer's growth.

The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct.,Ferraro G, Cirri D, Marzo T, Pratesi A, Messori L, Merlino A Dalton Trans. 2020 Dec 15. doi: 10.1039/d0dt04068a. PMID:33320144^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.